# US 11,839,642 B2 · Anti-angiogenin peptides, compositions, and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,839,642 B2
- Document ID: US11839642B2
- Status: Granted
- Kind: B2
- Application number: 16/623,684
- Filed: 2019-04-09
- Published: 2020-12-10
- Granted: 2023-12-12
- Earliest claimed: 2018-04-10
- Assignees: The Board of Regents of the University of Oklahoma
- Applicants: The Board of Regents of the University of Oklahoma
- Inventors: Chuanbin Mao; Yan Li
- Web page: https://patentgrep.com/patent/US11839642B2

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61P 35/00: Antineoplastic agents
- C07K 14/4703: {Inhibitors; Suppressors}
- C07K 17/00: Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N11/00); Preparation thereof
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C07K 14/005: from viruses
- C12N 2795/14132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/14171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Carrier compositions, including human-safe phages, equipped with one or more angiogenin-binding peptides, and optionally with tumor-homing peptides for use in anti-tumor therapies, are described. The angiogenin-binding peptides bind to and inactivate angiogenin molecules thereby blocking their angiogenic activity thus inhibiting angiogenesis in the tissue in which the compositions are localized.

## Claims

### Claim 1

A peptide composition, comprising:
a peptide linked to a carrier, the peptide comprising an amino acid sequence selected from the group consisting of WPYWNHHSHNNV (SEQ ID NO:1) and FHHPSIHDRHRH (SEQ ID NO:2), and variant sequences thereof, wherein the variant sequence has at least 83% identity with one of SEQ ID NO:1-2.

### Claim 2 (depends on 1)

The peptide composition of claim 1, further comprising a tumor-homing peptide linked to the carrier.

### Claim 3 (depends on 1)

The peptide composition of claim 1, wherein the carrier is selected from nanoparticles, liposomes, polymeric drug scaffolds and polymeric micelles.

### Claim 4 (depends on 3)

The peptide composition of claim 3, wherein the nanoparticle is a bacteriophage, bacteriophage fragment, virus, virus fragment, nano-cage, nano-rod, or nano-dendrite.

### Claim 5 (depends on 4)

The peptide composition of claim 4, wherein the bacteriophage or bacteriophage fragment is an M13, fl, or fd phage, or a fragment thereof.

### Claim 6 (depends on 1)

The peptide composition of claim 1, wherein the variant sequence has at least 91% identity to one of SEQ ID NO:1-2.

### Claim 7 (depends on 1)

The peptide composition of claim 1, wherein the peptide is directly linked by a covalent bond to the carrier.

### Claim 8 (depends on 1)

The peptide composition of claim 1, wherein the peptide is linked to the carrier via a linker sequence.

### Claim 9 (depends on 1)

The peptide composition of claim 1, wherein the peptide comprises the amino acid sequence SEQ ID NO:1, or the variant sequence thereof having at least 83% identity thereto.

### Claim 10 (depends on 1)

The peptide composition of claim 1, wherein the peptide comprises the amino acid sequence SEQ ID NO:2, or the variant sequence thereof having at least 83% identity thereto.

### Claim 11

A method of inhibiting angiogenesis in a subject in a subject in need of such therapy, comprising: administering to the subject an effective amount of a peptide composition comprising a peptide linked to a carrier, the peptide comprising an amino acid sequence selected from the group consisting of WPYWNHHSHNNV (SEQ ID NO:1) and FHHPSIHDRHRH (SEQ ID NO:2), and variant sequences thereof, wherein the variant sequence has at least 83% identity with one of SEQ ID NO:1-2.

### Claim 12 (depends on 11)

The method of claim 11, wherein the peptide composition further comprises a tumor-homing peptide linked to the carrier.

### Claim 13 (depends on 11)

The method of claim 11, wherein the carrier is selected from nanoparticles, liposomes, polymeric drug scaffolds and polymeric micelles.

### Claim 14 (depends on 13)

The method of claim 13, wherein the nanoparticle is a bacteriophage, bacteriophage fragment, virus, virus fragment, nano-cage, nano-rod, or nano-dendrite.

### Claim 15 (depends on 14)

The method of claim 14, wherein the bacteriophage or bacteriophage fragment is an M13, fl, or fd phage, or a fragment thereof.

### Claim 16 (depends on 11)

The method of claim 11, wherein the variant sequence has at least 91% identity to one of SEQ ID NO:1-2.

### Claim 17 (depends on 11)

The method of claim 11, wherein the peptide is directly linked by a covalent bond to the carrier.

### Claim 18 (depends on 11)

The method of claim 11, wherein the peptide is linked to the carrier via a linker sequence.

### Claim 19 (depends on 11)

The method of claim 11, wherein the peptide of the peptide composition comprises the amino acid sequence SEQ ID NO:1, or the variant sequence thereof having at least 83% identity thereto.

### Claim 20 (depends on 11)

The method of claim 11, wherein the peptide of the peptide composition comprises the amino acid sequence SEQ ID NO:2, or the variant sequence thereof having at least 83% identity thereto.